Pipeline And Margin Risks Will Challenge Rare Disease Expansion Narrative

Catalysts

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum focuses on rare disease medicines across hematology, immunology and specialty care.

What are the underlying business or industry changes driving this perspective?

• The planned launch of six high-value medicines by 2028 requires heavy development and commercial spending. If any of these programs are delayed, fail to gain approval or launch more slowly than expected, the current revenue base may not be sufficient to justify today’s valuation, with direct pressure on future revenue growth and earnings.
• The company is committing substantial capital to Arthrosi and its late stage gout asset. If competitive therapies, evolving treatment guidelines or safety and efficacy outcomes reduce the addressable market, this acquired program could fail to earn an adequate return, weighing on R&D productivity and long term net margins.
• Expansion into severe hypertriglyceridemia and broader cardiometabolic use for Tryngolza relies on specialist center adoption and later diffusion into community practice. Slower than expected physician uptake or payer restrictions could leave sales below current expectations, limiting operating leverage and EBITA margin improvement.
• The planned move into interferon gamma driven sepsis with Gamifant targets a large, complex acute care setting. If regulators require larger, costly trials, if pricing in intensive care units is more constrained than assumed or if identifying eligible patients at scale proves difficult, the revenue contribution could fall short of what is implied in the current equity story, keeping earnings and cash flow below optimistic scenarios.
• The global nephrology roll out of Aspaveli in C3G and IC MPGN depends on building a new treatment paradigm that includes earlier diagnosis, vaccination protocols and referral pathways. If screening does not expand or reimbursement and practical use barriers persist, uptake could remain modest relative to the investment, dampening revenue and putting sustained pressure on EBITA margins.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Swedish Orphan Biovitrum compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Swedish Orphan Biovitrum's revenue will grow by 10.1% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 4.5% today to 19.8% in 3 years time.
• The bearish analysts expect earnings to reach SEK 8.1 billion (and earnings per share of SEK 23.68) by about August 2029, up from SEK 1.4 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as SEK12.2 billion.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 19.5x on those 2029 earnings, down from 115.0x today. This future PE is lower than the current PE for the GB Biotechs industry at 33.6x.
• The bearish analysts expect the number of shares outstanding to grow by 0.76% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.78%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Sobi is reporting broad-based revenue growth, with Q4 2025 revenue of SEK 7.8b at 16% growth at constant currency and full year 2025 revenue just above SEK 28b at 15% growth at constant currency, alongside an adjusted EBITA margin of 40% for the year and 41% in Q4. This could support a stronger share price than a bearish view assumes by underpinning revenue and earnings.
• The product mix is shifting toward what management calls a high value strategic portfolio, which represented 65% of Q4 revenues and 59% of full year revenues, supported by assets like Altuvoct, Doptelet, Gamifant, Aspaveli and Tryngolza. This tilt toward higher margin therapies may support gross margin, currently at 81% in Q4, and sustain or improve net margins and long term earnings.
• An extensive late stage and launch pipeline, including six high value medicines planned to reach the market by 2028 such as Aspaveli in nephrology, Gamifant in interferon gamma driven sepsis, Tryngolza in severe hypertriglyceridemia and the late stage gout asset from Arthrosi, creates multiple long duration growth drivers. These could add to future revenue and expand EBITA over time if they are successfully commercialized.
• Strong cash generation and a relatively modest net debt profile, with operating cash flow of close to SEK 3b in Q4 2025, net debt of about SEK 10b and a net debt to EBITA ratio of 0.9x before the Arthrosi deal, give Sobi capacity to fund R&D and launches without relying excessively on external financing. This may help protect earnings and support long term margin resilience.
• Secular demand trends in Sobi’s focus areas, such as rare hematology, immunology, nephrology, severe hypertriglyceridemia and sepsis, combined with recent regulatory approvals and positive clinical data for products like Aspaveli, Gamifant and Tryngolza that are already published or accepted in major journals, may support sustained prescription growth across multiple regions and contribute to higher long term revenue and earnings than a declining share price scenario implies.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Swedish Orphan Biovitrum is SEK375.5, which represents up to two standard deviations below the consensus price target of SEK497.58. This valuation is based on what can be assumed as the expectations of Swedish Orphan Biovitrum's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK575.0, and the most bearish reporting a price target of just SEK350.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be SEK40.9 billion, earnings will come to SEK8.1 billion, and it would be trading on a PE ratio of 19.5x, assuming you use a discount rate of 5.8%.
• Given the current share price of SEK457.8, the analyst price target of SEK375.5 is 21.9% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.